RxDoctor Payments Data

Andres Mesa, MD

Cardiovascular Disease · Houston, TXNPI 1891721338

Payments from drug & device makers

$102,503in general payments, 2019–2025

Across 791 payments — averaging $129.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$74K
  • Bard Peripheral Vascular, Inc.$6K
  • Medtronic$6K
  • Boston Scientific$6K
  • Abbott$2K
  • Novartis$1K
  • plus $8K from 42 others

What the payments were for

  • Consulting fees$5,5005%
  • Speaking & faculty fees$65,05063%
  • Travel & lodging$10,63010%
  • Food & beverage$21,05721%
  • Education$2670%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$102,503 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$219,531
Medicare patients
184
Services billed
2,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban274$342,349
EntrestoSacubitril/Valsartan157$239,959
XareltoRivaroxaban113$152,424
JardianceEmpagliflozin117$126,302
FarxigaDapagliflozin Propanediol99$122,326
VascepaIcosapent Ethyl92$69,240
Repatha SureclickEvolocumab49$54,262
VerquvoVericiguat33$41,863
Icosapent Ethyl77$38,920
MounjaroTirzepatide24$27,213
Repatha SyringeEvolocumab22$23,399
NexlizetBempedoic Acid/Ezetimibe14$17,018
JanuviaSitagliptin Phosphate15$12,329
BrilintaTicagrelor11$11,508
Amiodarone Hcl112$9,388

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$155$342,349274 claims
NovartisEntresto$1,087$239,959157 claims
Johnson & JohnsonXarelto$939$152,424113 claims
AstraZenecaFarxiga, Brilinta$910$133,834110 claims
Boehringer IngelheimJardiance$647$126,302117 claims
MerckVerquvo, Januvia$641$54,19348 claims
Lilly USA, LLCMounjaro$24$27,21324 claims
Esperion Therapeutics, Inc.Nexlizet$254$17,01814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →